TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

在当地时间9月15日的中枢神经系统肿瘤简短口头报告专场，首都医科大学附属北京天坛医院李文斌教授就“A Phase I study for safety, tolerability, pharmacokinetics, and anti-tumor ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.

Severe obesity is already a significant problem for many children, especially since obese children often become obese adults. Could the now popular weight-loss injection drugs be a solution for those ...

2024年9月13-17日，2024年欧洲肿瘤内科学会（ESMO）年会于西班牙巴塞罗那正式召开。作为肿瘤领域最具权威的年度盛会之一，本届年会再次云集全球肿瘤大咖、汇聚领域最新进展。

英矽智能创始人兼首席执行官Alex Zhavoronkov博士表示：“ ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Shares of biopharma outfit Edgewise Therapeutics ( EWTX 47.93%) soared more than 50% today, reaching a three-year high ...

在此次ESC年会上展示的研究中，三联复方制剂GMRx2由替米沙坦、氨氯地平和吲达帕胺三种单药组成。研究结果显示，GMRx2在降低收缩压方面优于安慰剂组或单独使用替米沙坦、氨氯地平和吲达帕胺的组合降压疗法，且能使更多患者达到临床血压控制的目标。